Bronwyn E Grinton1, Sarah E Heron2,3, James T Pelekanos1,4,5, Sameer M Zuberi6, Sara Kivity7, Zaid Afawi8, Tristiana C Williams9, Dan M Casalaz10, Simone Yendle1, Ilan Linder11,12,13, Dorit Lev12,13,14, Tally Lerman-Sagie11,12,13, Stephen Malone15, Haim Bassan16, Hadassa Goldberg-Stern7, Thorsten Stanley17, Michael Hayman18,19, Sophie Calvert15, Amos D Korczyn20, Michael Shevell21, Ingrid E Scheffer1,22,23, John C Mulley9,24,25, Samuel F Berkovic1. 1. Epilepsy Research Centre, Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia. 2. Epilepsy Research Program, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia. 3. Sansom Institute for Health Research, University of South Australia, Adelaide, South Australia, Australia. 4. Department of Neurology, Royal Brisbane & Women's Hospital, Herston, Queensland, Australia. 5. UQ Centre for Clinical Research, The University of Queensland, Herston, Queensland, Australia. 6. Paediatric Neurosciences Research Group, Fraser of Allander Neurosciences Unit, Royal Hospital for Sick Children, Glasgow, United Kingdom. 7. Epilepsy Unit, Schneider Children's Medical Center of Israel, Petach Tikvah, Israel. 8. Tel-Aviv University Medical School, Tel-Aviv University, Tel-Aviv, Israel. 9. Department of Genetic Medicine, SA Pathology, Women's and Children's Hospital, North Adelaide, South Australia, Australia. 10. Department of Paediatrics, Mercy Hospital for Women, Heidelberg, Victoria, Australia. 11. Pediatric Neurology Unit, Wolfson Medical Center, Holon, Israel. 12. Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 13. Metabolic-Neurogenetic Clinic, Wolfson Medical Center, Holon, Israel. 14. Institute of Medical Genetics, Wolfson Medical Center, Holon, Israel. 15. Department of Neurosciences, Royal Children's Hospital, Brisbane, Queensland, Australia. 16. Pediatric Neurology and Development Unit, Tel Aviv Sourasky Medical Center, Dana Children's Hospital, Tel-Aviv, Israel. 17. Department of Paediatrics, School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand. 18. Department of Neurology, Royal Children's Hospital, Flemington, Victoria, Australia. 19. Department of Paediatrics, Monash Medical Centre, Clayton, Victoria, Australia. 20. Department of Neurology, Tel-Aviv University, Tel-Aviv, Israel. 21. Department of Pediatrics & Neurology, McGill University, Montreal, Quebec, Canada. 22. Department of Paediatrics, Royal Children's Hospital, The University of Melbourne, Flemington, Victoria, Australia. 23. The Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia. 24. School of Molecular and Biomedical Science, The University of Adelaide, Adelaide, South Australia, Australia. 25. School of Paediatrics and Reproductive Health, The University of Adelaide, Adelaide, South Australia, Australia.
Abstract
OBJECTIVE: We evaluated seizure outcome in a large cohort of familial neonatal seizures (FNS), and examined phenotypic overlap with different molecular lesions. METHODS: Detailed clinical data were collected from 36 families comprising two or more individuals with neonatal seizures. The seizure course and occurrence of seizures later in life were analyzed. Families were screened for KCNQ2, KCNQ3, SCN2A, and PRRT2 mutations, and linkage studies were performed in mutation-negative families to exclude known loci. RESULTS: Thirty-three families fulfilled clinical criteria for benign familial neonatal epilepsy (BFNE); 27 of these families had KCNQ2 mutations, one had a KCNQ3 mutation, and two had SCN2A mutations. Seizures persisting after age 6 months were reported in 31% of individuals with KCNQ2 mutations; later seizures were associated with frequent neonatal seizures. Linkage mapping in two mutation-negative BFNE families excluded linkage to KCNQ2, KCNQ3, and SCN2A, but linkage to KCNQ2 could not be excluded in the third mutation-negative BFNE family. The three remaining families did not fulfill criteria of BFNE due to developmental delay or intellectual disability; a molecular lesion was identified in two; the other family remains unsolved. SIGNIFICANCE: Most families in our cohort of familial neonatal seizures fulfill criteria for BFNE; the molecular cause was identified in 91%. Most had KCNQ2 mutations, but two families had SCN2A mutations, which are normally associated with a mixed picture of neonatal and infantile onset seizures. Seizures later in life are more common in BFNE than previously reported and are associated with a greater number of seizures in the neonatal period. Linkage studies in two families excluded known loci, suggesting a further gene is involved in BFNE. Wiley Periodicals, Inc.
OBJECTIVE: We evaluated seizure outcome in a large cohort of familial neonatal seizures (FNS), and examined phenotypic overlap with different molecular lesions. METHODS: Detailed clinical data were collected from 36 families comprising two or more individuals with neonatal seizures. The seizure course and occurrence of seizures later in life were analyzed. Families were screened for KCNQ2, KCNQ3, SCN2A, and PRRT2 mutations, and linkage studies were performed in mutation-negative families to exclude known loci. RESULTS: Thirty-three families fulfilled clinical criteria for benign familial neonatal epilepsy (BFNE); 27 of these families had KCNQ2 mutations, one had a KCNQ3 mutation, and two had SCN2A mutations. Seizures persisting after age 6 months were reported in 31% of individuals with KCNQ2 mutations; later seizures were associated with frequent neonatal seizures. Linkage mapping in two mutation-negative BFNE families excluded linkage to KCNQ2, KCNQ3, and SCN2A, but linkage to KCNQ2 could not be excluded in the third mutation-negative BFNE family. The three remaining families did not fulfill criteria of BFNE due to developmental delay or intellectual disability; a molecular lesion was identified in two; the other family remains unsolved. SIGNIFICANCE: Most families in our cohort of familial neonatal seizures fulfill criteria for BFNE; the molecular cause was identified in 91%. Most had KCNQ2 mutations, but two families had SCN2A mutations, which are normally associated with a mixed picture of neonatal and infantile onset seizures. Seizures later in life are more common in BFNE than previously reported and are associated with a greater number of seizures in the neonatal period. Linkage studies in two families excluded known loci, suggesting a further gene is involved in BFNE. Wiley Periodicals, Inc.
Authors: Renée A Shellhaas; Courtney J Wusthoff; Tammy N Tsuchida; Hannah C Glass; Catherine J Chu; Shavonne L Massey; Janet S Soul; Natrujee Wiwattanadittakun; Nicholas S Abend; Maria Roberta Cilio Journal: Neurology Date: 2017-07-21 Impact factor: 9.910
Authors: Ingrid E Scheffer; Samuel Berkovic; Giuseppe Capovilla; Mary B Connolly; Jacqueline French; Laura Guilhoto; Edouard Hirsch; Satish Jain; Gary W Mathern; Solomon L Moshé; Douglas R Nordli; Emilio Perucca; Torbjörn Tomson; Samuel Wiebe; Yue-Hua Zhang; Sameer M Zuberi Journal: Epilepsia Date: 2017-03-08 Impact factor: 5.864
Authors: Sarah B Mulkey; Bruria Ben-Zeev; Joost Nicolai; John L Carroll; Sabine Grønborg; Yong-Hui Jiang; Nishtha Joshi; Megan Kelly; David A Koolen; Mohamad A Mikati; Kristen Park; Phillip L Pearl; Ingrid E Scheffer; Rebecca C Spillmann; Maurizio Taglialatela; Silvia Vieker; Sarah Weckhuysen; Edward C Cooper; Maria Roberta Cilio Journal: Epilepsia Date: 2017-01-31 Impact factor: 5.864